APA (7th ed.) Citation

Peck-Radosavljevic, M., Boletis, J., Besisik, F., Ferraz, M. L., Alric, L., Samuel, D., . . . Cheinquer, H. (2008). 999 LOW-DOSE PEGINTERFERON ALFA-2A (40KD) (PEGASYS®) TO TREAT HEPATITIS C-INFECTED, END-STAGE RENAL DISEASE PATIENTS UNDERGOING HAEMODIALYSIS: FINAL STUDY RESULTS. Journal of Hepatology, 48, S374. https://doi.org/10.1016/S0168-8278(08)61001-6

Chicago Style (17th ed.) Citation

Peck-Radosavljevic, M., J. Boletis, F. Besisik, M. Lucia Ferraz, L. Alric, D. Samuel, D. Messinger, and H. Cheinquer. "999 LOW-DOSE PEGINTERFERON ALFA-2A (40KD) (PEGASYS®) TO TREAT HEPATITIS C-INFECTED, END-STAGE RENAL DISEASE PATIENTS UNDERGOING HAEMODIALYSIS: FINAL STUDY RESULTS." Journal of Hepatology 48 (2008): S374. https://doi.org/10.1016/S0168-8278(08)61001-6.

MLA (9th ed.) Citation

Peck-Radosavljevic, M., et al. "999 LOW-DOSE PEGINTERFERON ALFA-2A (40KD) (PEGASYS®) TO TREAT HEPATITIS C-INFECTED, END-STAGE RENAL DISEASE PATIENTS UNDERGOING HAEMODIALYSIS: FINAL STUDY RESULTS." Journal of Hepatology, vol. 48, 2008, p. S374, https://doi.org/10.1016/S0168-8278(08)61001-6.